Applied Genetic Technologies Corp. (NASDAQ:AGTC) rose 3.7% on Tuesday . The company traded as high as $15.89 and last traded at $15.76, with a volume of 104,504 shares trading hands. The stock had previously closed at $15.20.

AGTC has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Applied Genetic Technologies Corp. from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Wednesday, May 11th. Wells Fargo & Co. reiterated a “buy” rating on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $32.00 target price on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Roth Capital reiterated a “buy” rating on shares of Applied Genetic Technologies Corp. in a research note on Monday, April 25th. Finally, BMO Capital Markets initiated coverage on shares of Applied Genetic Technologies Corp. in a research note on Monday, April 11th. They set an “outperform” rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $26.00.

The firm’s market capitalization is $288.71 million. The stock’s 50 day moving average price is $15.05 and its 200 day moving average price is $15.07.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last announced its earnings results on Monday, May 9th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.06. The firm earned $12 million during the quarter, compared to analyst estimates of $12.98 million. During the same quarter last year, the business earned ($0.38) earnings per share. Applied Genetic Technologies Corp.’s revenue was up 4125.4% on a year-over-year basis. On average, analysts forecast that Applied Genetic Technologies Corp. will post ($0.16) earnings per share for the current year.

A number of large investors have recently made changes to their positions in AGTC. Russell Frank Co purchased a new stake in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at $1,541,000. Globeflex Capital L P purchased a new stake in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at $1,189,000. Finally, Jennison Associates LLC increased its stake in shares of Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock valued at $13,823,000 after buying an additional 3,248 shares during the period.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.